Epidemiology of late complications of diabetes: A basis for the development and evaluation of preventive programs

Joslin's Diabetes Mellitus: Fourteenth Edition

Volumn , Issue , 2011, Pages 795-808

  Krolewski, Andrzej S ^a,b   Warram, James H ^a,b  

^a JOSLIN DIABETES CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84970939206     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (169)

1. Krolewski AS, Warram JH. Epidemiology of late complications of diabetes. In: Kahn CR, Wier GC, eds. Joslin's diabetes mellitus, 13th ed. Philadelphia: Lea & Febiger, 1994:605-619.
2. MacGillivray MH, Voorhess ML, Putnam TI, et al. Hormone and metabolic profiles in children and adolescents with type 1 diabetes mellitus. Diabetes Care 1982;5[Suppl 1]:38-47.
3. Sowers JR, Lester MA. Diabetes and cardiovascular disease. Diabetes Care 1999;22[Suppl 3]:C14-C20.
4. Parving HH, Viberti GC, Keen H, et al. Hemodynamic factors in the genesis of diabetic microangiopathy. Metabolism 1983;32:943-949.
5. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. . Engl J Med 1988;318:1315-1321.
6. Greene D, Lattimer SA, Sima AAF. Sorbitol, phosphoinositides and sodiumpotassium-ATPase in the pathogenesis of diabetic complications. . Engl J Med 1987;316:599-606.
7. Krolewski AS, Warram JH, Rand LI, et al. Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. . Engl J Med 1987;317: 1390-1398.
8. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991;40:405-412.
9. King GL, Ishii H, Koya D. Diabetes vascular dysfunctions: a model of excessive activation of protein kinase C. Kidney Int 1997;52:S77-S85.
10. Singh BM, McNamara C, Wise PH. High variability of glycated hemoglobin concentrations in patients with IDDM followed for over 9 years. Diabetes Care 1997;20:306-308.
11. Antisdel JE, Anderson BJ, Warram JH, et al. Inherent tracking of glycemic control among patients with type 1 diabetes (submitted for publication).
12. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions of Complications Research Group. . Engl J Med 2000;342:381-389.
13. Palmberg P, Smith M, Waltman S, et al. The natural history of retinopathy in insulin-dependent juvenile-onset diabetes. Ophthalmology 1981;66:613-618.
14. Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984;102:520-526.
15. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. . Engl J Med 1993;329:977-986.
16. Krolewski AS, Warram JH, Rand LI, et al. Risk of proliferative diabetic retinopathy in juvenile-onset type I diabetes: a 40-yr follow-up study. Diabetes Care 1986;9:443-452.
17. Klein R, Klein BEK, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1989;107:237-243.
18. Orchard TJ, Dorman JS, Maser RE, et al. Pittsburgh epidemiology of diabetes complications study. II. Prevalence of complications in IDDM by sex and duration. Diabetes 1990;39:1116-1124.
19. Yokoyama H, Uchigata Y, Otani T, et al. Development of proliferative retinopathy in Japanese patients with IDDM: Tokyo Women's Medical College Epidemiologic Study. Diabetes Res Clin Pract 1994;24:113-119.
20. Klein R, Klein BEK, Moss SE, et al. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 1988;260:2864-2871.
21. Janka HU, Warram JH, Rand LI, et al. Risk factors for progression of background retinopathy in long-standing IDDM. Diabetes 1989;38:460-464.
22. Chase PH, Jackson WE, Hoops SL, et al. Glucose control and the renal and retinal complications of insulin-dependent diabetes. JAMA 1989;261:1155-1160.
23. Goldstein DE, Blinder KJ, Ide CH, et al. Glycemic control and development of retinopathy in youth-onset insulin-dependent diabetes mellitus. Results of a 12-year longitudinal study. Ophthalmology 1993;100:1125-1132.
24. Klein R, Klein BEK, Moss SE, et al. Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med 1994;154:2169-2178.
25. Cohen RA, Hennekens CH, Christen WG, et al. Determinants of retinopathy progression in type 1 diabetes mellitus. Am J Med 1999;107:45-51.
26. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive bloodglucose control on late complications of type I diabetes. Lancet 1993;341:1306-1309.
27. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. . Engl J Med 1993;329:304-309.
28. Diabetes Control and Complication Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the diabetes and complications trial. Ophthalmology 1995;102:647-661.
29. Warram JH, Manson JE, Krolewski AS. Glycated hemoglobin and the risk of retinopathy in insulin-dependent diabetes mellitus. . Engl J Med 1995;332: 1305-1306.
30. Danne T, Weber B, Hartmann R, et al. Long-term glycemic control as a nonlinear association to the frequency of background retinopathy in adolescents with diabetes. Diabetes Care 1994;17:1390-1396.
31. Janka HU, Ziegler AG, Valsania P, et al. Impact of blood pressure on diabetic retinopathy. Diabetes Metabol 1989;15:333-337.
32. Klein R, Klein BEK, Moss SE, et al. Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? Arch Intern Med 1989;149:2427-2432.
33. Norgaard K, Feldt-Rasmussen T, et al. Is hypertension a major independent risk factor for retinopathy in type I diabetes? Diabet Med 1991;8:334-337.
34. Chavers BM, Mauer SM, Ramsay RC, et al. Relationship between retinal and glomerular lesions in IDDM patients. Diabetes 1994;43:441-446.
35. Nathan DM. Long-term complications of diabetes mellitus. . Engl J Med 1993;328:1676-1685.
36. Klein R, Moss SE, Klein BEK. Is gross proteinuria a risk factor for the incidence of proliferative diabetic retinopathy? Ophthalmology 1993;100:1140-1146.
37. Krolewski AS, Barzilay J, Warram JH, et al. Risk of early-onset proliferative retinopathy in IDDM is closely related to cardiovascular autonomic neuropathy. Diabetes 1992;41:430-437.
38. Fong DS, Warram JH, Aiello LM, et al. Cardiovascular autonomic neuropathy and proliferative diabetic retinopathy. Am J Ophthalmol 1995;80:1882-1887.
39. Moss SE, Klein R, Klein BEK. Ocular factors in the incidence and progression of diabetic retinopathy. Ophthalmology 1994;101:77-83.
40. Gay AJ, Rosenbaum AL. Retinal artery pressure in asymmetric diabetic retinopathy. Arch Ophthalmol 1966;75:758-762.
41. Rand LI, Krolewski AS, Aiello LM, et al. Multiple factors in the prediction of risk of proliferative diabetic retinopathy. . Engl J Med 1985;313:1433-1438.
42. Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol 1994;112:1217-1228.
43. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117.
44. UK Prospective Diabetes Study (UKPDS). Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
45. Bojestig M, Arnqvist HJ, Hermansson G, et al. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. . Engl J Med 1993;330: 15-18.
46. Bojestig M, Arnqvist HJ, Karlberg BE, et al. Unchanged incidence of severe retinopathy in a population of type 1 diabetic patients with marked reduction of nephropathy. Diabet Med 1998;15:863-869.
47. Mogensen CE, Christensen CK, Vittinghus E. The stage in diabetic renal disease with emphasis on the stage of incipient diabetic nephropathy. Diabetes 1983;32[Suppl 2]:64-78.
48. Krolewski AS, Warram JH, Christlieb AR, et al. The changing natural history of nephropathy in type 1 diabetes. Am J Med 1985;78:785-794.
49. Janner M, Knill SE, Diem P, et al. Persistent microalbuminuria in adolescents with type I (insulin-dependent) diabetes mellitus is associated to early rather than late puberty-results of a prospective longitudinal study. Eur J Pediatr 1994;153:403-408.
50. Warram JH, Gearin G, Laffel LMB, et al. Effect of duration of type 1 diabetes on prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. . Am Soc Nephrol 1996;7:930-937.
51. Krolewski AS, Laffel LMB, Krolewski M, et al. Glycated hemoglobin and risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. . Engl J Med 1995;332:1251-1255.
52. Stephenson JM, Fuller JH. Microalbuminuria is not rare before 5 years of IDDM. . Diabetes Complications 1994;8:166-173.
53. Andersen AR, Christiansen JS, Andersen JK, et al. Diabetic nephropathy in type I (insulin-dependent) diabetes: an epidemiological study. Diabetologia 1983;25:496-501.
54. Perkins BA, Ficociello LH, Silva KH, et al. Regression of microalbuminuria in type 1 diabetes. . Engl J Med 2003;348:2285-2293.
55. Krolewski M, Eggers PW, Warram JH. Magnitude of end-stage renal disease in type I diabetes: a 35-year follow-up study. Kidney Int 1996;50:2041-2046.
56. Mathiesen ER, Ronn B, Storm B, et al. The natural course of microalbuminuria in insulin-dependent diabetes: a 10-year prospective study. Diabet Med 1995;12:482-487.
57. Coonrod BA, Ellis D, Becker DJ, et al. Predictors of microalbuminuria in individuals with IDDM. Diabetes Care 1993;16:1376-1383.
58. Risk factors for development of microalbuminuria in insulin dependent diabetic patients: a cohort study. Microalbuminuria Collaborative Study Group, United Kingdom. BMJ 1993;306:1235-1239.
59. Scott LJ, Warram JH, Hanna LS, et al. A nonlinear effect of hyperglycemia and current cigarette smoking are major determinants of the onset of microalbuminuria in type 1 diabetes. Diabetes 2001;50:2842-2849.
60. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int 1995;47: 1703-1720.
61. Krolewski AS, Warram JH. Glycated hemoglobin and risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. . Engl J Med 1995; 332:1251-1255.
62. Warram JH, Scott LJ, Hanna LS, et al. Progression of microalbuminuria to proteinuria in type 1 diabetes. Diabetes 2000;49:94-100.
63. Forsblom CM, Groop PH, Ekstrand A, et al. Predictive value of microalbuminuria in patients with insulin-dependent diabetes of long duration. BMJ 1992;305:1051-1053.
64. Almdal T, Norgaard K, Feldt-Rasmussen B, et al. The predictive value of microalbuminuria in IDDM: a five-year follow-up study. Diabetes Care 1994; 17:120-125.
65. Rudberg S, Dahlquist G. Determinants of progression of microalbuminuria in adolescents with IDDM. Diabetes Care 1996;19:369-371.
66. Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk. Is albumin excretion rate sufficient? Diabetes 2000;49:1399-1408.
67. Parving HH, Oxenboll B, Svendsen PA, et al. Early detection of patients at risk of developing diabetic nephropathy: a longitudinal study of urinary albumin secretion. Acta Endocrinol 1982;100:550-555.
68. Viberti GC, Hill RD, Jarrett RJ, et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982;1:1430-1432.
69. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulindependent patients. . Engl J Med 1984;311:89-93.
70. Feldt-Rasmussen B, Mathiesen ER, Deckert T. Effect of two-years of strict metabolic control on progression of incipient nephropathy in insulindependent diabetes. Lancet 1986;2:1300-1304.
71. Microalbuminuria Collaborative Study Group, United Kingdom. Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. BMJ 1995;311:973-977.
72. Mulec H, Blohme G, Grande B, et al. The effect of metabolic control on rate of decline in renal function in insulin-dependent diabetes mellitus with overt diabetic nephropathy. Nephrol Dial Transplant 1998;13:651-655.
73. Hovind P, Rossing P, Tarnow L, et al. Progression of diabetic nephropathy. Kidney Int 2001;59:702-709.
74. Viberti GC, Keen H, Wiseman MJ. Raised arterial pressure in parents of proteinuric insulin-dependent diabetics. BMJ 1987;295:515-517.
75. Krolewski AS, Canessa M, Warram JH, et al. Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. . Engl J Med 1988;318:140-145.
76. Barzilay J, Warram JH, Bak M, et al. Predisposition to hypertension: risk factor for nephropathy and hypertension in IDDM. Kidney Int 1992;41:723-730.
77. Fagerudd JA, Tarnow L, Jacobsen P, et al. Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients. Diabetes 1998;47:439-444.
78. Sawicki PT, Didjurgeit U, Muhllhauser I, et al. Smoking is associated with progression of diabetic nephropathy. Diabetes Care 1994;17:126-131.
79. Seaquist ER, Goetz FC, Rich S, et al. Familial clustering of diabetic kidney disease: evidence for genetic susceptibility to diabetic nephropathy. . Engl J Med 1989;320:1161-1165.
80. Borch-Johnsen K, Norgaard K, Hommel E, et al. Is diabetic nephropathy an inherited complication? Kidney Int 1992;41:719-722.
81. Quinn M, Angelico MC, Warram JH, et al. Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 1996;39:940-945.
82. The Diabetes Control and Complications Research Group. Clustering of long-term complications in families with diabetes in the Diabetes Control and Complication Trial. Diabetes 1997;46:1829-1839.
83. Krolewski AS. Genetics of diabetic nephropathy: evidence for major and minor gene effects. Kidney Int 1999;55:1582-1596.
84. Ballard DJ, Humphrey LL, Melton LJ, et al. Epidemiology of persistent proteinuria in type II diabetes mellitus. Population-based study in Rochester, Minnesota. Diabetes 1988;37:405-412.
85. Larson TS, Santanello N, Shahinfar S, et al. Trends in persistent proteinuria in adult-onset diabetes. Diabetes Care 2000;23:51-56.
86. Klein R, Klein BEK, Moss SC. Incidence of gross proteinuria in older-onset diabetes: a population-based perspective. Diabetes 1993;42:381-389.
87. Nosadini R, Solini A, Velussi M, et al. Impaired insulin-induced glucose uptake by extrahepatic tissue is hallmark of NIDDM patients who have or will develop hypertension and microalbuminuria. Diabetes 1994;43: 491-499.
88. Nelson RG, Pettitt DJ, Baird HR, et al. Pre-diabetic blood pressure predicts urinary albumin excretion after the onset of type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians. Diabetologia 1993;36:998-1001.
89. Faronato P, Maioli M, Tonolo G, et al. Clustering of albumin excretion rate abnormalities in Caucasian patients with NIDDM. Diabetologia 1997;40: 816-823.
90. Canani LH, Gerchman F, Gross JL. Familial clustering of diabetic nephropathy in Brazilian type 2 diabetic patients. Diabetes 1999;48:909-913.
91. Fogarty D, Rich SS, Hanna L, et al. Urinary albumin excretion in families with type 2 diabetes is heritable and genetically correlated with blood pressure. Kidney Int 2000;57:250-257.
92. Fogarty D, Hanna LS, Wantman M, et al. Segregation analysis of urinary albumin excretion in families with type 2 diabetes. Diabetes 2000;49:1057-1063.
93. Pettitt DJ, Saad MF, Bennett PH, et al. Familial predisposition to renal disease in two generations of Pima Indians with type II (non-insulin-dependent) diabetes mellitus. Diabetologia 1990;33:438-443.
94. Imperatore G, Knowler WC, Pettitt DJ, et al. Segregation analysis of diabetic nephropathy in Pima Indians. Diabetes 2000;49:1049-1056.
95. Freedman BI, Tuttle AB, Spray BJ. Familial predisposition to nephropathy in African Americans with non-insulin-dependent diabetes mellitus. Am J Kidney Dis 1995;25:710-713.
96. Neil A, Hawkins M, Potok M, et al. A prospective population-based study of microalbuminuria as a predictor of mortality in NIDDM. Diabetes Care 1993; 16:996-1003. 97 Stephenson JM, Kenny S, Stevens LK, et al. and the WHO Multinational Study Group. Proteinuria and mortality in diabetes: the WHO Multinational Study of Vascular Disease in Diabetes. Diabet Med 1995;12:149-155.
97. Nelson RG, Pettitt DJ, Carraher MJ, et al. Effect of proteinuria on mortality in NIDDM. Diabetes 1988;1499-1504.
98. Allawi J, Rao PV, Gilbert R, et al. Microalbuminuria in non-insulindependent diabetes: its prevalence in Indian compared with Europid patients. BMJ 1988;296:462-464.
99. Nelson RG, Kunzelman CL, Pettitt DJ, et al. Albuminuria in type 2 (noninsulin-dependent) diabetes mellitus and impaired glucose tolerance in Pima Indians. Diabetologia 1989;32:870-876.
100. Cowie CC. Diabetic renal disease: racial and ethnic differences from an epidemiologic perspective. Transplant Proc 1993;25:2426-2430.
101. Pugh JA, Stern MP, Haffner SM, et al. Excess incidence of treatment of endstage renal disease in Mexican Americans. Am J Epidemiol 1988;127:135-144.
102. Cowie CC, Port FK, Wolfe RA, et al. Disparities in the incidence of diabetic end-stage renal disease according to race and type of diabetes. . Engl J Med 1989;231:1074-1090.
103. Lee ET, Lee VS, Lu M, et al. Incidence of renal failure in NIDDM. The Oklahoma Indian diabetes study. Diabetes 1994;43:572-579.
104. Brancati FL, Whittle JC, Whelton PK, et al. The excess incidence of diabetic end-stage renal disease among blacks. JAMA 1992;268:3079-3084.
105. Kofoed-Enevoldsen A, Borch-Johnsen K, Kreiner S, et al. Declining incidence of persistent proteinuria in type I (insulin-dependent) diabetic patients in Denmark. Diabetes 1987;36:647-655.
106. Sawicki PT, Muhlhauser I, Didjurgeit U, et al. Effects of intensification of antihypertensive care in diabetic nephropathy. . Diabetes Complications 1995;9: 315-317.
107. Parving HH, Jacobsen P, Rossing K, et al. Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy. Kidney Int 1996;49: 1778-1782.
108. Centers for Disease Control and Prevention. Diabetes surveillance 1999. Atlanta: U.S. Department of Health and Human Services, 1999.
109. Harris MI. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 2000;23:754-758.
110. Viberti GC, Mogensen CE, Groop LC, et al. for the European Microalbuminuria Captopril Study Group. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 1994;271:275-279.
111. Laffel LMB, McGill JB, Gans DJ, on behalf of the North American Microalbuminuria Study Group. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med 1995;99:497-504.
112. Lewis EJ, Hunsicker LG, Bain RP, et al. for the Collaborative Study Group. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. . Engl J Med 1993;329:1456-1462.
113. Ritz E, Rychlik I, Locatelli F, et al. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999;34: 795-808.
114. Jarrett RI, Shipley MJ. Mortality and associated risk factors in diabetics. Acta Endocrinol 1985;110[Suppl 272]:21-26.
115. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993;16:434-444.
116. Krolewski AS, Kosinski EJ, Warram JH, et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 1987;59:750-755.
117. Stary HC. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. Arteriosclerosis 1989;9[Suppl I]:I19-I32.
118. Krolewski AS, Warram JH, Valsania P, et al. Evolving natural history of coronary artery disease in diabetes mellitus. Am J Med 1991;90[Suppl 2A]: 56S-61S.
119. Kleinman JC, Donahue RP, Harris MI, et al. Mortality among diabetics in a national sample. Am J Epidemiol 1988;2:389-401.
120. Jarrett RJ, Shipley MJ. Type 2 (non-insulin-dependent) diabetes mellitus and cardiovascular disease-putative association via common antecedents; further evidence from the Whitehall Study. Diabetologia 1988;31:737-740.
121. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of maturityonset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991;151:1141-1147.
122. Fontbonne A, Thibult N, Eschwege E, et al. Body fat distribution and coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes mellitus: the Paris Prospective Study, 15-year follow-up. Diabetologia 1992;35:464-468.
123. Walter SD, Holford TR. Additive, multiplicative, and other models for disease risks. Am J Epidemiol 1978;108; 341-346.
124. Rothman KJ. Occam's razor pares the choice among statistical models. Am J Epidemiol 1978;108:347-349.
125. Silberberg JS. Estimating the benefits of cholesterol lowering: are risk factors for coronary heart disease multiplicative? . Clin Epidemiol 1990;43:875-879.
126. Jarrett RJ. Mortality in diabetes. . J Med 1990;76:413-414.
127. Psaty BM, Koepsell TD, Manolio TA, et al. Risk ratios and risk differences in estimating the effect of risk factors for cardiovascular disease in the elderly. . Clin Epidemiol 1990;43:961-970.
128. Moss SE, Klein R, Klein BEK, et al. The association of glycemia and cause-specific mortality in a diabetic population. Arch Intern Med 1994;154:2473-2479.
129. Rossing P, Hougaard P, Borch-Johnsen K, et al. Predictors of mortality in insulin dependent diabetes: 10-year observational follow-up study. BMJ 1996; 313:779-784.
130. The Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995;75: 894-903.
131. Kuusisto J, Mykkanen L, Pyorala K, et al. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994;43:960-967.
132. Vander Zwaag R, Runyan JW, Davidson JK, et al. A cohort study of mortality in two clinic populations of patients with diabetes mellitus. Diabetes Care 1983;6:341-346.
133. Hillson RM, Hockaday TDR, Mann JI, et al. Hyperinsulinemia is associated with development of electrocardiographic abnormalities in diabetics. Diabetes Res 1984;1:143-149.
134. Janka HU, Ziegler AG, Stanndl E, et al. Daily insulin dose as a predictor of macrovascular disease in insulin treated non-insulin-dependent diabetics. Diabetes Metab 1987;13:359-364.
135. Ronnemaa T, Laakso M, Puukka P, et al. Atherosclerotic vascular disease in middle-aged, insulin-treated, diabetic patients: association with endogenous insulin secretion capacity. Atherosclerosis 1988;8:237-244.
136. Liu QZ, Knowler WC, Nelson RG, et al. Insulin treatment, endogenous insulin concentration, and ECG abnormalities in diabetic Pima Indians. Cross-sectional and prospective analyses. Diabetes 1992;41:1141-1150.
137. Stout RW. Insulin and atheroma: 20-yr perspective. Diabetes Care 1990;13: 631-654.
138. Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979;2:154-160.
139. Eschwege E, Richard JL, Thibult N, et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels: The Paris Prospective Study, ten years later. Horm Metab Res 1985;15[Suppl]: S41-S46.
140. Yarnel JWG, Sweetnam PM, Marks V, et al. Insulin in ischaemic heart disease: are associations explained by triglyceride concentration? The Caerphilly prospective study. Br Heart J 1994;71:293-296.
141. Jarrett RJ. Why is insulin not a risk factor for coronary heart disease? Diabetologia 1994;37:945-947.
142. Reaven GM, Laws A. Insulin resistance, compensatory hyperinsulinemia, and coronary heart disease. Diabetologia 1994;37:948-952.
143. Fontbonne A. Why can high insulin levels indicate a risk for coronary heart disease? Diabetologia 1994;37:953-955.
144. Stern MP. The insulin resistance syndrome: the controversy is dead, long live the controversy! Diabetologia 1994;37:956-958.
145. Adler AI, Neil AW, Manley SE, et al. Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom Prospective Diabetes Study (UKPDS 47). Am Heart J 1999;138:S353-S359.
146. Knatterud GL, Klimt CR, Levin ME, et al. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VII. Mortality and selected nonfatal events with insulin treatment. JAMA 1978; 240:37-42.
147. Haffner SM, Stern MP, Hazuda HP, et al. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990;263:2893-2898.
148. Martin BC, Warram JH, Krolewski AS, et al. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of 25-year follow-up study. Lancet 1992;340:925-929.
149. Howard G, O'Leary DH, Zaccaro D, et al. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 1996;93:1809-1817.
150. Borch-Johnsen K, Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. BMJ 1987;294:1651-1654.
151. Stephenson JM, Kenny S, Stevens LK, et al. Proteinuria and mortality in diabetes: the WHO multinational study of vascular disease in diabetes. Diabet Med 1995;12:149-155.
152. Gall MA, Borch-Johnsen K, Hougaard P, et al. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 1995;44:1303-1309.
153. Valmadrid CT, Klein R, Moss SE, et al. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 2000;160:1093-1100.
154. Earle K, Walker J, Hill C, et al. Familial clustering of cardiovascular disease in patients with insulin-dependent diabetes and nephropathy. . Engl J Med 1992;326:673-677.
155. Lahdenpera S, Groop PH, Tilly-Kiesi M, et al. LDL subclasses in IDDM patients: relation to diabetic nephropathy. Diabetologia 1994;37:681-688.
156. Warram JH, Laffel LMB, Ganda OP, et al. Coronary artery disease is the major determinant of excess mortality in patients with insulin-dependent diabetes mellitus and persistent proteinuria. . Am Soc Nephrol 1992;3[Suppl]:S104-S110.
157. Krolewski AS, Warram JH, Christlieb AR. Hypercholesterolemia-a determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int 1994;45[Suppl 45]:S125-S131.
158. Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycosylation end products in patients with diabetic nephropathy. . Engl J Med 1991;325:836-842.
159. Schwartz CJ, Kelley JL, Valente AJ, et al. Pathogenesis of the atherosclerotic lesion. Implications for diabetes mellitus. Diabetes Care 1992;15:1156-1167.
160. Diabetes Drafting Group. Prevalence of small vessel and large vessel disease in diabetic patients from 14 centres. The World Health Organisation Multinational Study of Vascular Disease in Diabetics. Diabetologia 1985;28[Suppl]: 615-640.
161. Head J, Fuller JH. International variation in mortality among diabetic patients. The WHO multinational study of vascular disease in diabetics. Diabetologia 1990;33:477-481.
162. Nelson RG, Sievers ML, Knowler WC, et al. Low incidence of fatal coronary heart disease in Pima Indians despite high prevalence of non-insulindependent diabetes. Circulation 1990;81:987-995.
163. Matsumoto T, Ohashi Y, Yamada N, et al. Coronary heart disease mortality is actually low in diabetic Japanese by direct comparison with the Joslin cohort. Diabetes Care 1994;17:1062-1063.
164. Stamler J. The marked decline in coronary heart disease mortality rates in the United States, 1968-81. Cardiology 1985;72:11-22.
165. Gillum RF. Trends in acute myocardial infarction and coronary heart disease death in the United States. . Am Coll Cardiol 1994;23:1273-1277.
166. McGovern PG, Pankow JS, Shahar E, et al. Recent trends in acute coronary heart disease. Mortality, morbidity, medical care and risk factors. . Engl J Med 1996;334:884-890.
167. Hunink MG, Goldman L, Tosteson ANA, et al. The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment. JAMA 1997;277:535-542.
168. Rosamond WD, Chambless LE, Folsom AR, et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987-. Engl J Med 1998;339:861-867.
169. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999;281:1291-1297.